THE PROJECT OF THE INDUSTRIAL PRODUCTION OF MICROSPHERES FOR COLORECTAL CANCER AND HEPATOCELLULAR CARCINOMA TREATMENT IS SUPPORTED BY MINISTRY OF INDUSTRY AND TRADE
At the annual reception of citizens by Minister of Trade and Industry, Denis Manturov, Director General of Bebig Company Kirill Mayorov discussed the issue of government support of industrial production of radiation microsources based on the radionuclide yttrium-90 for the treatment of colorectal cancer of the liver and hepatocellular carcinoma.
"Annually in Russia at least 7,000 people suffer from primary liver cancer and approximately 130 000 cases of cancer with metastasis to the liver are revealed. There are no standards of medical treatment for liver cancer. 75-90% of all liver tumors are inoperable", - Mayorov cited the statistics. Bebig has sufficient experience in the field of nuclear medicine. Since 2005, the Company has been supplying microsources for implantation into the prostate gland. This year the production of microsources was launched in Dubna.
Domestic radionuclide yttrium-90 microspheres represent similar TheraSphere® microspheres produced by Nordion Inc. Company, widely and successfully used in Europe, USA and Australia. In Russia foreign analogues have limitations in logistics due to a short half-life of radionuclide yttrium-90 equaling to 64 hours and high cost.
"Russian production of microspheres for the treatment of metastatic cancer of the liver and hepatocellular carcinoma will speed their delivery to hospitals and optimize costs. This means that patients with these serious diseases have a chance for recovery,"- said Kirill Mayorov, Bebig Director General.